Preferred Label : Ruxoprubart;
NCIt synonyms : Anti-Bb Monoclonal Antibody NM8074; Anti-Factor Bb Monoclonal Antibody NM8074;
NCIt definition : A humanized monoclonal antibody directed against complement factor Bb (FBb; Bb) that
can be used to treat various alternate pathway (AP)-mediated diseases. Upon administration,
ruxoprubart selectively targets, binds to and neutralizes Bb. This prevents the binding
of Bb to C3 and prevents the formation of protease C3 convertase (C3Bb). This prevents
the conversion of C3 into the fragments C3a and C3b, thereby preventing C3b deposition
and C3b-mediated extravascular hemolysis. Also, by preventing the formation of C3Bb,
C3Bb is unable to bind to C3b to form the protease C5 convertase (C3BbC3b). As C5
convertase is responsible for the conversion of C5 to C5a/C5b and initiation of membrane
attack complex (MAC), ruxoprubart is able to prevent MAC-mediated tissue damage. Altogether,
ruxoprubart inhibits the activation of the alternative complement pathway (ACP). Overactivation
of AP plays a key role in the initiation and propagation of C3b deposition, inflammation
and tissue destruction. Bb is created when complement factor D, a serine protease,
cleaves complement factor B into 2 fragments, Ba and Bb, in the AP of the complement
cascade. Ruxoprubart does not block the classical pathway (CP) which is critical for
host defense against infections.;
UNII : P9NB0SOG5X;
CAS number : 2842046-67-5;
Molecule name : NM 8074; NM-8074;
NCI Metathesaurus CUI : CL1906226;
Origin ID : C199294;
UMLS CUI : C5854409;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
